

CARDIOVASCULAR (CV) MEDICINES

MARKETED PRODUCTS

Crestor¹ (rosuvastatin calcium) is a member of the class of products known as statins and is used for the treatment of high cholesterol levels and, in the US, to slow the progression of atherosclerosis in patients with high cholesterol as an adjunct to diet.

Seloken/Toprol-XL (metoprolol succinate) is a once daily tablet for 24-hour control of blood pressure and for use in heart failure and angina.

Atacand² (candesartan cilexetil) is an angiotensin II antagonist for the first-line treatment of hypertension and symptomatic heart failure.

Tenormin (atenolol) is a cardioselective beta-blocker for hypertension, angina pectoris and other CV disorders.

Zestril³ (lisinopril dihydrate), an ACE inhibitor, is used for the treatment of a wide range of CV diseases, including hypertension.

Plendil (felodipine) is a calcium antagonist for the treatment of hypertension and angina.

2007 IN BRIEF

- > **Crestor sales up 33% to \$2.8 billion. Over 12 million patients treated and more than 114 million prescriptions written since launch.**
- > **New atherosclerosis indication for Crestor approved in the US. EU prescribing information updated with positive atherosclerosis data.**
- > **Atacand sales up 9% to \$1.3 billion.**
- > **Worldwide (except Japan) collaboration with Bristol-Myers Squibb to develop and commercialise two investigational compounds for the treatment of Type 2 diabetes – saxagliptin and dapagliflozin.**
- > **Generic versions of Toprol-XL now being marketed in the US at all dosage strengths.**
- > **Sales of Toprol-XL in the US down 30%.**
- > **Patent infringement actions filed against seven generic drug manufacturers in the US following abbreviated new drug applications relating to Crestor.**

PERFORMANCE

	2007			2006			2005	2007 compared to 2006		2006 compared to 2005	
	Sales \$m	Growth underlying \$m	exchange effects \$m	Sales \$m	Growth underlying \$m	exchange effects \$m		Growth underlying %	Growth reported %	Growth underlying %	Growth reported %
Crestor	2,796	673	95	2,028	745	15	1,268	33	38	59	60
Seloken/Toprol-XL	1,438	(393)	36	1,795	62	(2)	1,735	(22)	(20)	3	3
Atacand	1,287	99	78	1,110	133	3	974	9	16	14	14
Tenormin	308	(24)	12	320	(24)	(8)	352	(8)	(4)	(7)	(9)
Zestril	295	(30)	18	307	(23)	(2)	332	(10)	(4)	(7)	(8)
Plendil	271	(20)	16	275	(86)	1	360	(7)	(1)	(24)	(24)
Other	291	(14)	22	283	(27)	(1)	311	(5)	2	(9)	(9)
Total	6,686	291	277	6,118	780	6	5,332	5	9	15	15

PIPELINE

Compound	Mechanism	Areas under investigation	Phase			Estimated filing date		
			I	II	III	Europe	US	
NCEs								
AZD6140	ADP receptor antagonist	arterial thrombosis	■	■	■		2H 2009	2H 2009
Saxagliptin	dipeptidyl peptidase-4 (DPP-4) inhibitor	diabetes	■	■	■		2H 2009	2Q 2008
Dapagliflozin	sodium-glucose cotransporter-2 (SGLT2) inhibitor	diabetes	■	■	■		2010	2010
Crestor/ABT-335	statin + fibrate fixed combination	dyslipidaemia	■	■	■			2H 2009
AZD0837	thrombin inhibitor	thrombosis	■	■	■		2012	2012
AZD4121	cholesterol absorption inhibitor	dyslipidaemia	■	■	■			
AZD2207	CB1 antagonist	diabetes/obesity	■	■	■			
AZD1175	CB1 antagonist	diabetes/obesity	■	■	■			
AZD1305	anti-arrhythmic	arrhythmias	■	■	■			
AZD6370	GLK activator	diabetes	■	■	■			
Line extensions								
Atacand	angiotensin II antagonist	diabetic retinopathy	■	■	■		1H 2009	1H 2009
Atacand Plus	angiotensin II antagonist/thiazide diuretic	32/12.5 mg, 32/25 mg for hypertension	■	■	■		2Q 2008	
Crestor	statin	atherosclerosis	■	■	■		Launched	Launched
Crestor	statin	outcomes end stage renal disease	■	■	■		1H 2009	1H 2009
Crestor	statin	outcomes in subjects with elevated CRP	■	■	■		2010	2010
Saxagliptin/metformin FDC	DPP-4 + biguanide FDC	diabetes	■	■	■			
Dapagliflozin/metformin FDC	SGLT2 + biguanide FDC	diabetes	■	■	■			

For discontinued projects see page 30.

¹ Licensed from Shionogi & Co., Ltd.

² Licensed from Takeda Chemical Industries Ltd.

³ Licensed from Merck & Co., Inc..